Australian-New Zealand Clinical Trial: A Phase 1/2, Double-blinded, Randomised, Active Controlled, Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 valent Human Papillomavirus Virus (10vHPV) Vaccine in Comparison with Gardasil 9 Vaccine in Healthy Adults

Australia, Oct. 28 -- The Australian New Zealand Clinical Trials Registry (ANZCTR) received information related to the study titled ‘A Phase 1/2, Double-blinded, Randomised, Active Controlled, Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 valent Human Papillomavirus Virus (10vHPV) Vaccine in Comparison with Gardasil 9 Vaccine in Healthy Adults’. The following are the other relevant details related to the trial:

Trial ID: 392578

Submit Date: 9/9/26 14:00

Study Type: Interventional

Intervention: The intervention used in this study is called 10vHPV. There are two phases in this study. Phase 1 will test 0.5mL single dose of 10vHPV on Day 1, in healthy participants. Phase 2 will test 0.5mL sing...